Document is current
Any future updates will be listed below
-
Authors
Tada, Yayoi https://orcid.org/0000-0003-3743-135X
Imafuku, Shinichi
Sugiura, Kazumitsu
Fujita, Hideki
Tsuruta, Noriko
Mitsuma, Teruyuki
Yoshizaki, Ayumi
Abe, Masatoshi
Yamaguchi, Yukie
Morita, Akimichi
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 26 February 2025
First Online: 22 March 2025
Declarations
:
: Yayoi Tada has received grants, consultancy/speaker's honoraria, and honoraria as an advisory board member from Boehringer Ingelheim. Shinichi Imafuku has received grants from AbbVie, Eisai, Kyowa Kirin, Taiho Pharmaceutical, Mitsubishi Tanabe, Tsumura, Torii Pharmaceutical, Maruho, LEO Pharma, Sun Pharmaceutical Industries, Kaken, Nippon Zoki Pharmaceutical, Sato Pharmaceutical, Eli Lilly, and Sanofi; received consulting activities fees from Meiji Seika Pharma, Bristol Myers Squibb, JT, LEO Pharma, Boehringer Ingelheim, Pfizer, Maruho, and UCB; received speaker’s honoraria from Astellas Pharma, AbbVie, Eli Lilly, Otsuka Pharmaceutical, Kaken, Kyowa Kirin, Sato Pharmaceutical, Sanofi, Sun Pharmaceutical Industries, GSK, Amgen, Daiichi Sankyo, Takeda Pharmaceutical, Taiho Pharmaceutical, Mitsubishi Tanabe, Tsumura, Torii Pharmaceutical, Nippon Zoki Pharmaceutical, Novartis, Pfizer, Bristol Myers Squibb, Maruho, LEO Pharma, Janssen, and UCB; and received honoraria as an advisory board member from Kyowa Kirin, Pfizer, LEO Pharma, AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim. Kazumitsu Sugiura has received grants from AbbVie, Eli Lilly, Maruho, Taiho Pharmaceutical, Eisai, Kyowa Kirin, and Boehringer Ingelheim; received consulting fees from AbbVie, Janssen, Boehringer Ingelheim, Eli Lilly, and LEO Pharma; received speaker’s honoraria from AbbVie, Eisai, Janssen, LEO Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Kyowa Kirin, Maruho, Novartis, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB; and received support for attending meetings and/or travel from AbbVie, Janssen, Boehringer Ingelheim, Eli Lilly, Kyowa Kirin, Novartis, Taiho Pharmaceutical, and UCB. Hideki Fujita has received grants from Maruho, Taiho, Torii Pharmaceutical, Kaken, Eisai, Kyowa Kirin, and Sun Pharmaceutical Industries; received consultancy/speaker's honoraria from Boehringer Ingelheim, AbbVie, LEO Pharma, Taiho Pharmaceutical, Amgen, Eisai, Eli Lilly, Janssen, JMEC, Kyowa Kirin, Maruho, Mitsubishi Tanabe, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, UCB, Ushio, and Bristol Myers Squibb; and received honoraria as an advisory board member from Boehringer Ingelheim, AbbVie, LEO Pharma, Sun Pharmaceutical Industries, UCB. Noriko Tsuruta has received consulting fees from Boehringer Ingelheim. Teruyuki Mitsuma has nothing to disclose. Ayumi Yoshizaki has received speaker’s honoraria and payment for expert testimony from Boehringer Ingelheim. Masatoshi Abe has received speaker’s honoraria from Taiho Pharmaceutical, Sanofi, Maruho, Eli Lilly, Amgen, AbbVie, Torii Pharmaceutical, Kyowa Kirin, and Novartis. Yukie Yamaguchi has received grants from Maruho, Taiho Pharmaceutical, Sun Pharmaceutical Industries, Kyowa Kirin, Eli Lilly, Mitsubishi Tanabe, and Torii Pharmaceutical; received consulting honoraria from UCB, LEO Pharma, Taiho Pharmaceutical, and Boehringer Ingelheim; and received speaker’s honoraria from UCB, Eli Lilly, Janssen, Amgen, LEO Pharma, Mitsubishi Tanabe, Bristol Myers Squibb, Taiho Pharmaceutical, AbbVie, Kyowa Kirin, Novartis, and Sun Pharmaceutical Industries. Akimichi Morita has received grants from AbbVie, Kyowa Kirin, LEO Pharma, Maruho, Torii Pharmaceutical, Taiho Pharmaceutical, Mitsubishi Tanabe, Sun Pharmaceutical Industries, and Eisai; received consulting honoraria from Boehringer Ingelheim, Novartis, AbbVie, Nichi-Iko, and Nippon Kayaku; received speaker’s honoraria from AbbVie, Eli Lilly, Eisai, Janssen, Kyowa Kirin, Maruho, Mitsubishi Tanabe, Pfizer, Sun Pharmaceutical Industries, Torii Pharmaceutical, UCB, Taiho Pharmaceutical, and Novartis; and received honoraria as an advisory board member from Bristol Myers Squibb, GSK, Eli Lilly, Kyowa Kirin, Pfizer, and UCB.
: This type of study does not require any patient information, hence no ethical review or approval was necessary. The study utilized data from anonymized experts’ answers, and all experts involved in the e-Delphi were included as authors.
